Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Valneva

Status: Completed

Conditions: Japanese Encephalitis

Treatments: Biological: Japanese Encephalitis purified inactivated vaccine

Study type: Observational

Funder types: Industry

Identifiers

NCT00596102

IC51-303

Details and patient eligibility

About

The study investigates the long term safety and immunogenicity of the Japanese Encephalitis vaccine IC51 up to month 60.

Enrollment: 3,258 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy subjects at least 18 years of age
• Written informed consent obtained prior to study entry
• Subjects correctly included and having completed clinical studies IC51-301 (NCT00604708) and IC51-302 (NCT00605085) with at least one vaccination

Exclusion criteria

• Inability or unwillingness to provide informed consent and to abide the requirements of the study